Aetna have now changed their policy and no longer consider NxStage experimental. I believe that Home Dialyzors United were instrumental in achieving this change. I hope that you can now progress with your desire to switch to NxStage. Good luck.
Aetna Policy Update on Home Dialysis Devices/Equipment FYI, Aetna Insurance has updated there policy on home dialysis. The CPB has been revised to state that the NxStage Hemodialysis System is an acceptable alternative to the Standard Home Dialysis Systems. I advise reading the policy change based on many professional references. If you click on additional information on the Aetna Clinical Policy Bulletin Notes on the right hand of the page, it explains what criteria where used in determining the policy change.
Below is a list of references from the actual policy that were used in determining the change. Other than the National Kidney Foundation, I do not see any other advocacy groups mentioned. .
The above policy is based on the following references: 1.U.S. Department of Health and Human Services, Health Care Financing Administration (HCFA). Medicare Coverage Issues Manual §§ 55-1 - 55-3. Baltimore, MD: HCFA; 1999.
2.Tricenturion LLC. Home dialysis supplies and equipment. Durable Medical Equipment Program Safeguard Contractor (DME PSC). Medicare Local Coverage Determination (LCD) No. 11498. Columbia, SC: Tricenturion; revised January 1, 2006.
3.Association for the Advancement of Medical Instrumentation (AAMI), American National Standards Institute. Hemodialysis systems. In: AAMI standards and recommended practices. Volume 3: dialysis. Arlington, VA: AAMI; 1995.
4.Medical Devices Directorate. Haemodialysis equipment: Review issue. London, UK: Department of Health; 1992.
5.U.S. Department of Health and Human Services, National Institutes of Health (NIH), Office of Medical Applications of Research. Morbidity and mortality of dialysis. NIH Consensus Statement. Bethesda, MD: NIH; November 1-3, 1993; 11(2):1-33. Available at:
http://odp.od.nih.gov/consensus. Accessed March 20, 2000.
6.National Kidney Foundation (NKF). NKF-DOQI clinical practice guidelines for vascular access. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis. 1997;30(4 Suppl 3):S150-S191.
7.National Kidney Foundation (NKF). NKF-DOQI clinical practice guidelines for hemodialysis adequacy. Am J Kidney Dis. 1997;30(3 Suppl 2):S15-S66.
8.National Kidney Foundation (NKF). NKF-DOQI clinical practice guidelines for peritoneal dialysis adequacy. Am J Kidney Dis. 1997;30(3 Suppl 2):S67-S136.
9.Steuer RR, Harris DH, Conis JM. A new optical technique for monitoring hematocrit and circulating blood volume: Its application in renal dialysis. Dialysis Transplantation. 1993;22(5):260-264.
10.Steuer RR, Leypoldt JK, Cheung AK, et al. Hematocrit as an indicator of blood volume and a predictor of intradialytic morbid events. Am Soc Artificial Internal Organs J. 1994;40(3):M691-M695.
11.Steuer RR, Harris DH, Conis JM. Continuous, in-line monitoring of oxygen saturation in hemodialysis. Dialysis Transplantation. 1995;24(11):615-620, 658.
12.Steuer RR, Leypoldt JK, Cheung AK, et al. Reducing symptoms during hemodialysis by continuously monitoring the hematocrit. Am J Kidney Dis. 1996;17(4):525-532.
13.Agraharkar M, Barclay C, Agraharkar A. Staff-assisted home hemodialysis in debilitated or terminally ill patients. Int Urol Nephrol. 2002;33(1):139-144.
14.National Institute for Clinical Excellence (NICE). Guidance on home compared with hospital haemodialysis for patients with end-stage renal failure. Technology Appraisal Guidance 48. London, UK: NICE; September 2002. Available at:
http://www.nice.org.uk/Docref.asp?d=36748. Accessed February 4, 2004.
15.Mowatt G, Vale L, MacLeod A. Systematic review of the effectiveness of home versus hospital or satellite unit hemodialysis for people with end-stage renal failure. Int J Technol Assess Health Care. 2004;20(3):258-268.
16.Vale L, Cody J, Wallace S, et al. Continuous ambulatory peritoneal dialysis (CAPD) versus hospital or home haemodialysis for end-stage renal disease in adults. Cochrane Database Syst Rev. 2004;(4):CD003963.
17.Rabindranath KS, Strippoli GF, Daly C, et al. Haemodiafiltration, haemofiltration and haemodialysis for end-stage kidney disease. Cochrane Database Syst Rev. 2006;(4):CD006258.
18.Rabindranath KS, Adams J, Ali TZ, et al. Continuous ambulatory peritoneal dialysis versus automated peritoneal dialysis for end-stage renal disease. Cochrane Database Syst Rev. 2007;(2):CD006515.
19.Topfer LA. Portable home hemodialysis. Emerging Technology List. No. 25. Ottawa, ON: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); March 2005.
20.Suri RS, Nesrallah GE, Mainra R, et al. Daily hemodialysis: A systematic review. Clin J Am Soc Nephrol. 2006;1(1):33-42.
21.Danish Centre for Evaluation and Health Technology Assessment (DACEHTA). Dialysis in chronic renal failure - a health technology assessment. Danish Health Technology Assessment. Copenhagen, Denmark: DACEHTA; 2006;8(3).
22.McFarlane PA, Bayoumi AM, Pierratos A, Redelmeier DA. The impact of home nocturnal hemodialysis on end-stage renal disease therapies: A decision analysis. Kidney Int. 2006;69(5):798-805.
23.Al-Hilali N, Al-Humoud H, Nampoory M, et al. Outcome and survival in different peritoneal dialysis modalities. Ther Apher Dial. 2007;11(2):101-106.
24.Kraus M, Burkart J, Hegeman R, et al. A comparison of center-based vs. home-based daily hemodialysis for patients with end-stage renal disease. Hemodial Int. 2007;11(4):468-477.
25.Davenport A, Gura V, Ronco C, et al. A wearable haemodialysis device for patients with end-stage renal failure: A pilot study. Lancet. 2007;370(9604):2005-2010.
26.Scott A. Portable home hemodialysis for kidney failure. Issues in Emerging Health Technologies Issue 108. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health; 2007. Available at:
http://cadth.ca/media/pdf/E0046_Portable-Home-Hemodialysis_cetap_e.pdf. Accessed June 25, 2008.
27.National Horizon Scanning Centre (NHSC). Tap water home haemodialysis systems for end stage renal failure: Horizon scanning technology briefing. Birmingham, UK: NHSC; 2007.
28.Purins A, Hiller JE. NxStage System One home dialysis for patients waiting for kidney transplantation. Australia and New Zealand Horizon Scanning Network. Prioritising Summary. Canberra, ACT: Australian Government; November 2008;22:1-5.
29.Jaber BL, Finkelstein FO, Glickman JD, et al. Scope and design of the Following Rehabilitation, Economics and Everyday-Dialysis Outcome Measurements (FREEDOM) Study. Am J Kidney Dis. 2009;53(2):310-320.
30.Mundy L, Hiller JE. Wearable artificial kidney (WAK): Portable dialysis for patients with chronic kidney disease. Adelaide, SA: Adelaide Health Technology Assessment (AHTA). Horizon Scanning Prioritising Summary; 2009;25.
31.Jaber BL, Lee Y, Collins AJ, et al. ; FREEDOM Study Group. Effect of daily hemodialysis on depressive symptoms and postdialysis recovery time: Interim report from the FREEDOM (Following Rehabilitation, Economics and Everyday-Dialysis Outcome Measurements) Study. Am J Kidney Dis. 2010;56(3):531-539.
32.Gossage-Worrall R, Armstrong J, Clift M. Portable haemodialysis devices. Evidence Review. CEP10053. London, UK: National Health Service, Purchasing and Supply Agency, Centre for Evidence-based Purchasing; 2010.
33.Weinhandl ED, Liu J, Gilbertson DT, et al. Survival in daily home hemodialysis and matched thrice-weekly in-center hemodialysis patients. J Am Soc Nephrol. 2012;23(5):895-904.
Here is a llink to the Entire Policy Change: http://www.aetna.com/cpb/medical/data/500_599/0541.html